March 1, 1994PEDIATRICS
Monitoring for Anthracycline Cardiotoxicity
Why the study?
Does serial cardiac monitoring and subsequent anthracycline dose modification based on abnormal cardiac findings reduce overall morbidity and mortality in cancer patients without clinical evidence of cardiac dysfunction?
Population
Cancer patients receiving anthracycline therapy without clinical evidence of cardiac dysfunction
Comparison
Serial cardiac monitoring and subsequent… vs Prospectively followed control population…
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Should not yet guide anthracycline dosing without prospective controls; leaves open the value of serial monitoring in asymptomatic patients.
Structured PICO
Does serial cardiac monitoring and subsequent anthracycline dose modification based on abnormal cardiac findings reduce overall morbidity and mortality in cancer patients without clinical evidence of cardiac dysfunction?
P
Population
Cancer patients receiving anthracycline therapy without clinical evidence of cardiac dysfunction
I
Intervention
Serial cardiac monitoring and subsequent anthracycline dose modification based on abnormal cardiac findings
C
Comparator
Prospectively followed control population without dose modification
O
Outcome
Cardiac morbidity and related mortality, oncologic morbidity and mortality, and overall morbidity and mortalityhard clinical
There is a lack of prospective, controlled data to support routine anthracycline dose modification based solely on abnormal cardiac monitoring findings in asymptomatic patients.
Cite This Study
Lipshultz et al. (1994) studied this question.